Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.

@article{Bjrkander2006ProspectiveOS,
  title={Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.},
  author={Janne Bj{\"o}rkander and Jukka Nikoskelainen and Heinz Leibl and Peter Lanbeck and J Wallvik and Jukka T Lumio and J. H. Braconier and Borislava G. Pavlova and Karl Birthistle and Werner Engl and Silke Walter and Hartmut J. Ehrlich},
  journal={Vox sanguinis},
  year={2006},
  volume={90 4},
  pages={286-93}
}
BACKGROUND AND OBJECTIVES The aim of this study was to evaluate the pharmacokinetics, efficacy and safety of a newly developed 10% liquid immunoglobulin preparation in patients with primary immunodeficiency diseases. This new preparation for intravenous use includes three dedicated virus clearance steps in its manufacturing process to ensure a high margin… CONTINUE READING